The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

Globe Investor

News Sources

Take control of your investments with the latest investing news and analysis

Press release from PR Newswire

Janssen and Johnson & Johnson to Present Results from Five Pivotal Phase 3 Studies Evaluating Investigational Canagliflozin for the Treatment of Type 2 Diabetes

Tuesday, June 05, 2012

Janssen and Johnson & Johnson to Present Results from Five Pivotal Phase 3 Studies Evaluating Investigational Canagliflozin for the Treatment of Type 2 Diabetes09:24 EDT Tuesday, June 05, 2012NEW BRUNSWICK, N.J., June 5, 2012 /PRNewswire/ -- Janssen and Johnson & Johnson (NYSE: JNJ) will provide investors and other interested parties an overview presentation of results from five pivotal Phase 3 studies evaluating investigational canagliflozin for the treatment of Type 2 Diabetes on Sunday, June 10 at approximately 2:00 p.m., Eastern Time. These data will be presented at the American Diabetes Association annual meeting in Philadelphia, Pa. The presentation can be accessed by visiting the Johnson & Johnson website at www.investor.jnj.com and clicking on "Webcasts/Presentations."SOURCE Johnson & JohnsonFor further information: Press, Al Wasilewski, +1-732-524-1130, Bill Price, +1-732-524-6623, or Investor, Stan Panasewicz, +1-732-524-2524, Louise Mehrotra, +1-732-524-6491